Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Renstar LLC

Neither a doctor nor a teaching hospital

Research payments

$4,671,293

607 payments

Through program year 2025, Renstar LLC is reported as receiving $4,671,293 in research payments, across 607 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,114,124 123
2024 Research $1,103,392 127
2023 Research $575,966 106
2022 Research $927,427 108
2021 Research $129,520 23
2020 Research $351,493 53
2019 Research $469,370 67

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $1,453,868 155 payments
  2. Pfizer Inc. $715,971 95 payments
  3. Janssen Research & Development, LLC $511,961 128 payments
  4. Ucb SA $450,241 2 payments
  5. AbbVie, Inc. $405,086 99 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $347,840 54 payments
  7. Amgen Inc. $251,807 2 payments
  8. Roche Products Limited $184,434 29 payments
  9. Aclaris Therapeutics, Inc. $166,869 16 payments
  10. Celgene Corporation $79,312 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinson's Disease $396,231 1 payment
  2. Postgraduate Roll Over Study $385,550 38 payments
  3. Phase 2 Double Blind Randomized Study in IPF and SSc ILD $378,886 42 payments
  4. A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $311,379 28 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $247,732 1 payment
  6. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $210,675 22 payments
  7. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $186,691 35 payments
  8. Q1w Dosing $175,295 26 payments
  9. A Phase 2A Randomized Doubleblind Sponsoropen Placebocontrolled Parallel Group Doseranging Study of Pf07976016 to Assess Safety and Efficacy in Adult Participants With Obesity $173,880 11 payments
  10. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $166,869 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record